Breaking News, Trials & Filings

FDA Lifts Clinical Hold on Cell Therapeutics Drug

Phase II Tosedostat trials in blood cancer resume

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cell Therapeutics, Inc. has received notification from FDA lifting the partial clinical hold on tosedostat (IND 075503), allowing all studies to continue. Tosedostat, a selective inhibitor of aminopeptidases, which are necessary for growth and tumor cell survival, is under development for the treatment of blood-related cancers. Tosedostat is currently being studied in Phase II trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters